Home » Stocks » ACET

Adicet Bio, Inc. (ACET)

Stock Price: $12.09 USD -0.11 (-0.90%)
Updated Apr 20, 2021 4:00 PM EDT - Market closed
Market Cap 383.51M
Revenue (ttm) 17.90M
Net Income (ttm) -36.68M
Shares Out 7.32M
EPS (ttm) -5.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 20
Last Price $12.09
Previous Close $12.20
Change ($) -0.11
Change (%) -0.90%
Day's Open 12.17
Day's Range 11.76 - 12.46
Day's Volume 72,992
52-Week Range 1.11 - 21.40

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

MENLO PARK, Calif. and BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...

1 week ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, March 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...

1 month ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, March 04, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer a...

1 month ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell thera...

2 months ago - GlobeNewsWire

MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other dis...

2 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...

2 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies fo...

2 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Jan. 07, 2021 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

3 months ago - GlobeNewsWire

Adicet Bio is a biotechnology company concentrated on developing allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a pre-clinical pipeline of 4 therapeutics cov...

3 months ago - Seeking Alpha

Adicet Bio (ACET) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

4 months ago - Zacks Investment Research

MENLO PARK, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapies for cance...

4 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

4 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Nov. 06, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

5 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

5 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing first-in-class allogeneic gamma delta T cell therapie...

5 months ago - GlobeNewsWire

Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell non-Hodgkin's lymphoma Phase 1 Clinical Study will Evaluate ADI-001 Safety and Efficacy in Patients with B-cell n...

5 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer an...

6 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Sept. 22, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer...

6 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies...

6 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (“Adicet”) (Nasdaq: ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies...

7 months ago - GlobeNewsWire

MENLO PARK, Calif. and BOSTON, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq:  ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cance...

7 months ago - GlobeNewsWire

MENLO PARK, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- Adicet Bio, Inc. (Nasdaq:  ACET), a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other...

7 months ago - GlobeNewsWire

- Adicet Emerges as a Leading Allogeneic Gamma Delta T Cell Therapy Company Focused on Oncology -

Other stocks mentioned: TORC
7 months ago - GlobeNewsWire

BOSTON, July 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or trea...

Other stocks mentioned: TORC
8 months ago - GlobeNewsWire

NEW YORK, July 28, 2020 /PRNewswire/ -- TrialSpark, a tech-enabled drug development partner committed to improving the speed, quality, and innovation of clinical trials, today announced a collaboration ...

Other stocks mentioned: TORC
8 months ago - PRNewsWire

BOSTON, July 28, 2020 (GLOBE NEWSWIRE) -- resTORbio resTORbio, Inc. (Nasdaq: TORC) today announced the award from the National Institute on Aging to fund a randomized, double-blind, placebo-controlled...

Other stocks mentioned: TORC
8 months ago - GlobeNewsWire

NEW YORK, June 29, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of resTORbio, Inc. ("TORC" or the "Company...

Other stocks mentioned: TORC
9 months ago - PRNewsWire

ResTORbio's Reverse Merger With Adicet Should Unlock Substantial Value For Shareholders

Other stocks mentioned: TORC
11 months ago - Seeking Alpha

BOSTON, April 30, 2020 (GLOBE NEWSWIRE) -- resTORbio, Inc. (Nasdaq: TORC) today announced that due to the public health impact of the coronavirus pandemic and to prioritize the health and well-being o...

Other stocks mentioned: TORC
11 months ago - GlobeNewsWire

BOSTON, April 03, 2020 (GLOBE NEWSWIRE) -- resTORbio (Nasdaq: TORC) today announced that it will postpone enrollment in the fifth cohort of its ongoing Phase 1b/2a trial of RTB101, an orally administe...

Other stocks mentioned: TORC
1 year ago - GlobeNewsWire

ResTORbio Is Trading At Less Than Half Of Its Net Cash After Crash

Other stocks mentioned: TORC
1 year ago - Seeking Alpha

The company's lead drug candidate flopped an important clinical trial, which has investors questioning the validity of the pipeline's approach.

Other stocks mentioned: TORC
1 year ago - The Motley Fool

There is a huge risk-reward factor in emerging pharmaceutical and biotech companies that happen to have all their eggs in just one basket.

Other stocks mentioned: TORC
1 year ago - 24/7 Wall Street

Analysis indicates RTB101 upregulates innate antiviral immunity to prevent clinically symptomatic respiratory illnesses caused by multiple viruses in older adults Analysis indicates RTB101 upregulates i...

Other stocks mentioned: TORC
1 year ago - GlobeNewsWire

BOSTON, Sept. 23, 2019 (GLOBE NEWSWIRE) -- resTORbio, Inc., (Nasdaq: TORC), a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or tr...

Other stocks mentioned: TORC
1 year ago - GlobeNewsWire

TORC has done tolerably well since IPO-ing last year, producing solid phase 2 results from lead drug candidate RTB101.

Other stocks mentioned: TORC
1 year ago - Seeking Alpha

As of late, it has definitely been a great time to be an investor in resTORbio.

Other stocks mentioned: TORC
1 year ago - Zacks Investment Research

About ACET

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase 1 clinical study for the treatment of non-Hodgkin's lymphoma. The company a... [Read more...]

Industry
Medicinal and Botanical Manufacturing
Founded
1947
CEO
Chen Schor
Employees
81
Stock Exchange
NASDAQ
Ticker Symbol
ACET
Full Company Profile

Financial Performance

In 2020, Adicet Bio's revenue was $17.90 million, an increase of 1,699.30% compared to the previous year's $995,000. Losses were -$36.68 million, 30.4% more than in 2019.

Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for Adicet Bio stock is "Strong Buy." The 12-month stock price forecast is 26.25, which is an increase of 117.12% from the latest price.

Price Target
$26.25
(117.12% upside)
Analyst Consensus: Strong Buy